Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Xeris Biopharma Holdings Inc. diskutieren

Xeris Biopharma Holdings Inc.

WKN: A3C4ZC / Symbol: XERS / Name: Xeris Biopharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

1,63 €
-0,31 %

Einschätzung Buy
Rendite (%) 91,14 %
Kursziel 5,67
Veränderung
Endet am 09.03.24

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for XERS provided by MarketBeat

Einschätzung Buy
Rendite (%) -24,49 %
Kursziel 5,44
Veränderung
Endet am 10.08.24

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for XERS provided by MarketBeat

Einschätzung Buy
Rendite (%) -23,07 %
Kursziel 4,16
Veränderung
Endet am 28.08.24

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $4.50 price target on the stock.
Ratings data for XERS provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,94 %
Kursziel 3,74
Veränderung
Endet am 10.11.24

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target lowered by analysts at Piper Sandler from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Ratings data for XERS provided by MarketBeat

Einschätzung Buy
Rendite (%) -23,24 %
Kursziel 4,62
Veränderung
Endet am 28.03.25

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
Ratings data for XERS provided by MarketBeat